Johnson & Johnson (JNJ Q1FY20) – Identified a lead COVID 19 vaccine candidate which can be the growth factor.

in , on June 25, 2020

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new pediatric formulation of SIRTURO® (bedaquiline). SIRTURO® is now indicated for use as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multidrug-resistant tuberculosis (MDR‑TB). In the U.S., the medicine should be reserved for use when an effective treatment regimen cannot otherwise be provided.

Executive Summary

Financial Statements

– Income Statement and Forecast
– Balance Sheet
– Cash Flow
– Q1FY20 Results Overview
– Q1FY20 Segment Performance
– Q1FY20 Developments
– FY20 Guidance
– Conclusion
– GAAP to Non GAAP Reconciliation

Historical Performance

– Key Ratios
– Profitability Ratios, Asset Turnover Ratio, Growth Ratio
– Per Share Items and Key Ratios
– Key Balance Sheet Items and Cash Flow Items
– P/E Band

Product Performance and Key Developments

–Key Developments

Valuation and Consensus Performance

– Relative Valuation
– Analyst Recommendations

Market Price Performance 

CrispIdea Coverage


Release Information

  • Released

    June 25, 2020

  • Last Updated

    June 25, 2020